+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030- Product Image
Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030- Product Image
Sale

Diabetic Retinopathy Market by Product Type (Anti-VEGF Agents, Corticosteroids, Laser Equipment), Diabetic Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), Patient Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 5788863
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Retinopathy Market grew from USD 9.07 billion in 2024 to USD 9.62 billion in 2025. It is expected to continue growing at a CAGR of 6.21%, reaching USD 13.02 billion by 2030.

Diabetic retinopathy, a leading cause of vision impairment, represents a critical challenge in modern healthcare. As the prevalence of diabetes escalates globally, the complications stemming from this condition are becoming increasingly prominent, pushing healthcare stakeholders to innovate and adapt. The market has evolved through rapid scientific advancements and improved diagnostic techniques, offering both opportunities and challenges in patient management. Researchers and clinicians now leverage sophisticated imaging technologies alongside novel pharmacological interventions and surgical procedures to slow progression in affected patients. This development has stimulated significant interest among investors and policy-makers, who are committed to funding research and expanding treatment options.

In parallel with these clinical advances, policymakers and healthcare providers are re-examining patient management protocols, emphasizing early detection and personalized treatment strategies. This evolving perspective is reshaping the landscape, where practice guidelines are frequently updated to reflect the latest advancements. As a result, stakeholders across pharmaceutical, medical device, and clinical research domains are closely monitoring trends and regulatory updates. The interplay between technological innovation and strategic investments is undoubtedly shaping new patient outcomes, making it a pivotal time for the industry.

Transformative Shifts in the Diabetic Retinopathy Market

The diabetic retinopathy market is undergoing transformative shifts driven by groundbreaking research, rapid technological advances, and evolving regulatory frameworks. Innovations in imaging techniques, such as optical coherence tomography and retinal photography, have refined early detection procedures and enabled more accurate monitoring of disease progression. This evolution has not only enhanced diagnostic precision but also paved the way for the development of targeted therapies that address underlying pathological changes.

A significant milestone in market transformation has been the establishment of integrated care models. These models foster cross-functional collaborations between ophthalmologists, endocrinologists, and primary care providers to streamline patient care. The incorporation of telemedicine and digital health platforms has further expanded access to expert consultation and continuous disease monitoring, particularly in remote or underserved areas. Regulatory authorities have also been more supportive, fast-tracking approvals for promising treatments which in-turn has accelerated market dynamics.

This dynamic environment has redefined competitive strategies, encouraging industry leaders to invest in research and development, while exploring novel partnerships and mergers. Such adaptations are critical to remaining competitive in a market where rapid advancements dictate continuous evolution, ultimately benefiting both patients and broader healthcare systems.

Key Segmentation Insights Shaping Market Strategies

A deep dive into market segmentation reveals nuanced insights that are guiding current and future strategies for addressing diabetic retinopathy. First, the product-type segmentation illustrates diversity in treatment approaches including anti-VEGF agents, corticosteroids, laser equipment, and surgical implants. Anti-VEGF agents, specifically those like aflibercept, bevacizumab, and ranibizumab, offer innovative solutions to inhibit abnormal blood vessel growth, while corticosteroids such as dexamethasone and triamcinolone provide alternative mechanisms to manage inflammation and edema. Each of these options reflects the multifaceted treatment paradigm required to address varied patient needs.

Further, segmentation based on diabetic type distinguishes between non-proliferative and proliferative diabetic retinopathy, emphasizing varied severity and treatment responsiveness. Differentiating patient type into adult and pediatric categories underscores the necessity of tailored diagnostic and therapeutic interventions, accounting for physiological and developmental differences. End-user segmentation - covering ambulatory surgical centers, clinics, and hospitals - further nuances market strategies, with clinics (encompassing both general and specialty forms) and hospitals (divided into private and public sectors) requiring customized deployment of technologies and therapies. The detailed segmentation analysis thus provides a robust framework for precision targeting and strategic investments.

Based on Product Type, market is studied across Anti-VEGF Agents, Corticosteroids, Laser Equipment, and Surgical Implants. The Anti-VEGF Agents is further studied across Aflibercept, Bevacizumab, and Ranibizumab. The Corticosteroids is further studied across Dexamethasone and Triamcinolone.

Based on Diabetic Type, market is studied across Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.

Based on Patient Type, market is studied across Adult and Pediatric.

Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.

Regional Trends and Opportunities in Diabetic Retinopathy Management

Geographical variations play a seminal role in shaping the diabetic retinopathy landscape, with market dynamics reflecting distinct regional trends and opportunities. In the Americas, a maturing healthcare infrastructure and increased awareness about diabetes complications have driven significant demand for advanced diagnostic and therapeutic options. This has paved the way for higher adoption rates of novel treatments and comprehensive patient management systems.

In the combined region of Europe, Middle East & Africa, diverse economic and healthcare framework create a unique interplay between advanced treatment solutions and emerging markets that are witnessing rapid growth. Regulatory environments in developed countries support sophisticated healthcare interventions, whereas emerging regions are implementing large-scale programs to address increasing disease burden and infrastructural constraints.

Asia-Pacific represents one of the fastest growing markets, fueled by a surge in diabetes prevalence and rapid urbanization. The region's focus on cost-effective yet innovative therapies drives a unique blend of traditional practices with modern medical advancements, creating a fertile environment for market players. These regional insights signal that while technology and regulatory support remain key drivers across the board, tailored strategies are essential to address local market conditions and economic diversity.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Corporate Innovation and Leadership Driving Market Growth

The competitive landscape is defined by a cast of global and regional industry leaders whose efforts are continually reshaping diabetic retinopathy management. Established pharmaceutical giants alongside innovative medical device companies are at the forefront of developing next-generation treatments and diagnostic tools. Industry veterans such as AbbVie Inc., Amgen Inc., Bayer AG, and F. Hoffmann-La Roche AG are contributing extensive research capabilities and resources to drive market expansion. Companies like AEYE Health, Ocular Therapeutix, Inc., and Eyenuk, Inc. are recognized for their disruptive innovations in digital imaging and treatment delivery.

In parallel, organizations like ANI Pharmaceuticals, Inc., Bausch + Lomb Corporation, Boehringer Ingelheim International GmbH, and Novartis AG are leveraging expertise to optimize therapeutic regimens through combination therapies. Emerging players including Clearside Biomedical, Inc. and Ocuphire Pharma, Inc. are making significant inroads with focused research on localized drug delivery systems. Additionally, firms such as Kodiak Sciences Inc., Ocugen, Inc., and OcuTerra Therapeutics are forging ahead with pioneering clinical trials that promise to redefine treatment paradigms. Other notable contributors, including Opthea Limited, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., RetinaRisk, RETMARKER, and Samsung Biologics Co., Ltd., exert considerable influence on market innovation. This convergence of corporate innovation and leadership is key to developing effective, next-wave solutions in the management of diabetic retinopathy.

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AEYE Health, Amgen Inc., ANI Pharmaceuticals, Inc., Bausch + Lomb Corporation, Bayer AG, BCN Peptides, S.A.U., Boehringer Ingelheim International GmbH, Clearside Biomedical, Inc., Eli Lilly and Company, Eyenuk, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., OcuTerra Therapeutics, Opthea Limited, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., RetinaRisk, RETMARKER, and Samsung Biologics Co., Ltd..

Actionable Recommendations for Industry Leaders

The shifting dynamics of diabetic retinopathy signify a pressing need for strategic realignment among industry stakeholders. It is imperative for market leaders to invest robustly in research and development, particularly in those areas where emerging technologies such as advanced imaging systems and targeted drug delivery platforms show promise. Collaborative efforts between research institutions and industry players can accelerate the development cycle from conceptualization to clinical validation.

Leaders should also focus on leveraging data analytics to inform decision-making processes, ensuring that every strategic move aligns with current market demands and patient needs. Embracing digital transformation can optimize operational efficiencies and improve patient outreach through telemedicine and remote diagnostic platforms. Furthermore, proactive engagement with regulatory bodies will be essential for navigating the complex approval processes associated with innovative treatment modalities. Such integrated approaches will not only drive market growth but also enhance the capability to deliver care tailored to diverse patient populations.

The insights drawn from the diabetic retinopathy landscape highlight an industry in transformation, marked by rapid technological progress, enhanced segmentation, and evolving regional trends. The convergence of innovative therapies, advanced diagnostic platforms, and novel market segmentation strategies contributes to a robust and competitive ecosystem. As researchers, clinicians, and commercial stakeholders continue to adapt to these changes, the focus remains on improving patient outcomes and expanding treatment horizons.

Looking ahead, sustained investments in cross-sector collaborations and digital health initiatives are expected to address the growing demand for precision medicine in diabetic retinopathy. This proactive trajectory promises to yield comprehensive benefits, from heightened patient care standards to enhanced market growth, cementing the future of diabetic retinopathy management as both innovative and patient-centric.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Government initiatives and funding for diabetes management and retinal care boosting research and development
5.1.1.2. Increasing prevalence of diabetes and rising awareness about early eye disease detection fueling market growth
5.1.2. Restraints
5.1.2.1. High costs of treatment and limited access to healthcare in emerging economies restricting market expansion
5.1.3. Opportunities
5.1.3.1. Advancements in diagnostic technologies and introduction of novel therapies enhancing patient outcomes
5.1.3.2. Growing interest in mobile health applications enabling patient education on diabetic retinopathy prevention
5.1.4. Challenges
5.1.4.1. Lack of adequate screening programs and late diagnosis leading to irreversible vision loss
5.2. Market Segmentation Analysis
5.2.1. Product Type: Growing need for corticosteroids to alleviate inflammation and reduce macular edema
5.2.2. Diabetic Type: Increasing prevelance of non-proliferative diabetic retinopathy
5.2.3. Patient Type: Growing instances of diabetic retinopathy in adults ages due to the prolonged duration of diabetes
5.2.4. End-User: Rising preference for ambulatory surgical centers to provide accessible and specialized care for diabetic retinopathy patients
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Diabetic Retinopathy Market, by Product Type
6.1. Introduction
6.2. Anti-VEGF Agents
6.2.1. Aflibercept
6.2.2. Bevacizumab
6.2.3. Ranibizumab
6.3. Corticosteroids
6.3.1. Dexamethasone
6.3.2. Triamcinolone
6.4. Laser Equipment
6.5. Surgical Implants
7. Diabetic Retinopathy Market, by Diabetic Type
7.1. Introduction
7.2. Non-Proliferative Diabetic Retinopathy
7.3. Proliferative Diabetic Retinopathy
8. Diabetic Retinopathy Market, by Patient Type
8.1. Introduction
8.2. Adult
8.3. Pediatric
9. Diabetic Retinopathy Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.3.1. General Clinics
9.3.2. Specialty Clinics
9.4. Hospitals
9.4.1. Private Hospitals
9.4.2. Public Hospitals
10. Americas Diabetic Retinopathy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Diabetic Retinopathy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Diabetic Retinopathy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Scenario Analysis
13.3.1. Retina Consultants of America to be acquired by Cencora for up to USD 5.1 billion
13.3.2. Eyenuk and AAO partner to bring diabetic retinopathy screening to underserved communities
13.3.3. Google partners with Indian and Thai healthcare businesses to combat diabetic retinopathy using AI technology
13.3.4. Innovative partnership leverages advanced AI technology to enhance diabetic retinopathy screening efforts
13.3.5. Merck acquires EyeBio for USD 3 billion
13.3.6. DocGo and Spect partner to reduce care gaps and improve eye and vision health
13.3.7. ANI Pharmaceuticals to acquire Alimera Sciences
13.3.8. FDA's approval of AEYE Health's autonomous AI transforms diabetic retinopathy screening using portable devices
13.3.9. Exonate's groundbreaking EXN407 eye drop shows promise in treating diabetic retinopathy and macular oedema
13.3.10. PolyPhotonix receives NPIF backing for diabetic retinopathy mask
13.4. Strategy Analysis & Recommendation
13.4.1. Novartis AG
13.4.2. Eli Lilly and Company
13.4.3. Bayer AG
13.4.4. AbbVie Inc.
List of Figures
FIGURE 1. DIABETIC RETINOPATHY MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC RETINOPATHY MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
FIGURE 4. DIABETIC RETINOPATHY MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 17. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 19. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 25. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DIABETIC RETINOPATHY MARKET DYNAMICS
TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 60. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 62. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 63. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 104. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 105. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 106. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 112. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 113. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 128. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 129. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 130. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 174. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 176. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 177. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 178. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 181. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 201. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 202. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 203. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 209. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 210. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 211. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 225. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 226. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 227. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 234. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 238. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 249. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 250. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 251. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 279. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 281. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 282. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 287. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 289. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 290. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 319. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 321. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 322. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 323. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 324. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 325. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 326. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 335. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 336. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 337. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 343. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 344. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 345. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 346. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 3

Companies Mentioned

  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.02 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Non-Proliferative Diabetic Retinopathy Market Report 2025 - Product Image

Non-Proliferative Diabetic Retinopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032 - Product Image

Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Proliferative Diabetic Retinopathy (PDR) Market Report 2025 - Product Image

Proliferative Diabetic Retinopathy (PDR) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Diabetic Retinopathy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Diabetic Retinopathy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From

About the Diabetic Retinopathy Market

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated. Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss. In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR. The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR. Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.